



## Invitation to presentation of Acarix´s first quarter 2025 report

Acarix invites investors, analysts, and media representatives to join a recorded webcast presentation of the first quarter report for 2025, scheduled for May 12<sup>th</sup> at 15:00 CET. The presentation will be led by CEO Aamir Mahmood and will be conducted in English. Questions can be submitted via email in advance to [Christian.lindholm@acarix.com](mailto:Christian.lindholm@acarix.com) until 17:00 CET on May 7th.

The report will be released in the morning on May 12<sup>th</sup>. Additionally, the presentation will be available on the Acarix website.

### About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

### For more information, contact

Ashley Wilson, phone +1405 413 5201, email [awilson@saxum.com](mailto:awilson@saxum.com)

### Attachments

[Invitation to presentation of Acarix´s first quarter 2025 report](#)